Felix Hilpert

5PUBLICATIONS

82CO-AUTHORS

Cancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|Jun 12, 2026

Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

|Nov 03, 2025

Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Aug 15, 2023

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Rachel N Grisham, Ignace Vergote, Susana Banerjee

|Nov 04, 2022

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen

|Aug 24, 2022

Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.

Pauline Wimberger, Mara Julia Gerber, Jacobus Pfisterer

Pageof 1

Frequent Collaborators

Jalid Sehouli

Pauline Wimberger

Gunnar Kristensen

Jacobus Pfisterer

Alexander Burges

Philipp Harter

Lars Hanker

Willibald Schröder

Florian Heitz

Tjoung-Won Park-Simon

Frequent Collaborators

Jalid Sehouli

Pauline Wimberger

Gunnar Kristensen

Jacobus Pfisterer